PeptideClinicLocatorOverview
AOD-9604 is a modified fragment of human growth hormone (the 177-191 region). It has been marketed for fat metabolism, weight loss, and cartilage repair without the full effects of growth hormone. Despite interest, AOD-9604 is not FDA-approved and cannot be legally compounded in the US. Its nomination was withdrawn from Category 2 in September 2024—but withdrawal does not make it legal. It has no USP monograph and is not an approved drug, so there is no pathway for legal compounding. Evidence in humans is limited; most data are animal or preclinical.
How It Works (Mechanism of Action)
The 177-191 fragment is thought to influence fat metabolism and possibly cartilage without full GH receptor activation. Mechanisms are not fully established in humans.
Primary Uses
Marketed uses include fat loss and cartilage support. Evidence is emerging—limited human trials, mostly animal/preclinical. Not a legal option for human use in the US.
FDA & Regulatory Status
Prohibited for compounding. Nomination withdrawn from Category 2 (September 27, 2024). Withdrawal removed it from the active list but did not create a legal pathway. No USP monograph; not FDA-approved. Cannot be legally compounded.
Last reviewed February 2026.
Clinical Evidence
Emerging—limited human trials, mostly animal/preclinical.
